Jpmorgan Chase & CO Cytek Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 608,440 shares of CTKB stock, worth $3.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
608,440
Previous 85,412
612.36%
Holding current value
$3.28 Million
Previous $573,000
492.5%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CTKB
# of Institutions
129Shares Held
74.7MCall Options Held
200Put Options Held
100-
Black Rock Inc. New York, NY17.1MShares$92 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$63.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD11.4MShares$61.4 Million1.3% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$35.9 Million0.96% of portfolio
-
State Street Corp Boston, MA3.97MShares$21.4 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $726M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...